2. Signaling Pathways
  3. GPCR/G Protein
  4. LPL Receptor
  5. S1PR2 Isoform
  6. S1PR2 Agonist

S1PR2 Agonist

S1PR2 Agonists (5):

Cat. No. Product Name Effect Purity
  • HY-12355
    Siponimod
    		Agonist 99.95%
    Siponimod (BAF-312) is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis.
  • HY-111253
    CYM-5478
    		Agonist 99.90%
    CYM-5478 is a potent and highly selective S1P2 agonist with an EC50 of 119 nM in a TGFα-shedding assay. CYM-5478 protects neural-derived cell lines against Cisplatin toxicity.
  • HY-12355A
    Siponimod hemifumarate
    		Agonist 99.64%
    Siponimod (BAF-312) hemifumarate is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod hemifumarate induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod hemifumarate can be used in research related to multiple sclerosis.
  • HY-113934
    L-threo Lysosphingomyelin (d18:1)
    		Agonist 98.0%
    L-threo Lysosphingomyelin (d18:1) (L-threo-Sphingosylphosphorylcholine) is an endogenous bioactive sphingolipid. L-threo Lysosphingomyelin (d18:1) is a potent S1P receptor agonist with EC50s of 19.3, 131.8, and 313.3 nM for hS1P1, hS1P3, and hS1P2, respectively.
  • HY-182618
    XAX-162
    		Agonist
    XAX-162 is a highly selective sphingosine 1-phosphate receptor 2 (S1PR2) agonist with a human EC50 of 0.55 μM. XAX-162 does not activate other S1P receptors. XAX-162 exhibits noncompetitive inhibition of activity by S1PR2 antagonist JTE-013 (HY-100675).